These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17301554)

  • 1. [International clinical trials for a medical oncologist in Japan].
    Nakagawa K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):320-3. PubMed ID: 17301554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current problems of early phase clinical trials for new anticancer agents in Japan].
    Nakagawa K; Fukuoka M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):925-9. PubMed ID: 10897223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Participation in the international multi-countries study-operational issues from company view point].
    Hada S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):324-7. PubMed ID: 17301555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-boundary cancer studies at the University of Tokyo: Oncology in Asian countries: clinical development challenges and opportunities.
    Rigaudy P
    Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i54-59. PubMed ID: 24516214
    [No Abstract]   [Full Text] [Related]  

  • 6. [Globalization of clinical trials].
    Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Future directions of anticancer drug development in Japan].
    Akaza H; Kawai K; Tsuruo T; Tsukagoshi S; Aiba K; Shimada Y; Kakeji Y; Ishikawa H; Ikeda T; Nakamura S; Tamura T; Yamamoto N; Isonishi S; Hinotsu S; Hirose M; Katsura J
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):351-60. PubMed ID: 18281781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
    Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
    Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan.
    Boku N
    Jpn J Clin Oncol; 2010 Mar; 40(3):183-7. PubMed ID: 20047861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
    Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Participation to international registration trials--from the investigator's standpoint].
    Ohtsu A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmaceutical industry and oncology in central and eastern Europe.
    Ben-Am M; Gemperli B; Covelli A; Burke G
    Ann Oncol; 1999; 10 Suppl 6():15-7. PubMed ID: 10676548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status and problems in clinical trial for new anticancer drug in Japan].
    Fukuoka M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):141-5. PubMed ID: 8611040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
    Park K; Goto K
    Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
    Kock M; Thomsen MK
    Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Operational aspect of participation in the multi-national clinical trials from the foreign pharmaceutical company's standpoint].
    Namazu K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):328-30. PubMed ID: 17301556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Participation in the global study. Activities and issues from the bedside].
    Yamamoto N
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):316-9. PubMed ID: 17301553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.